🇺🇸 FDA

Drug profile · INN

clofazimine

LAMPRENE

FDA: approved
US status
approved
Patents linked
4
News articles
0

Quick answer

clofazimine (LAMPRENE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN clofazimine
Brand LAMPRENE
Route ORAL
Formulation CAPSULE

Related patents

Search patents →

  1. US 11090326

    Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine

    Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10143702

    Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine

    Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9314477

    Compositions comprising rifabutin, clarithromycin, and clofazimine and uses thereof

    Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9198926

    Methods and compositions comprising rifabutin, clarithromycin, and clofazimine

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is clofazimine?

clofazimine (LAMPRENE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for clofazimine?

LAMPRENE is a marketed brand name for clofazimine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of clofazimine?

clofazimine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.